Lyell Immunopharma Inc (LYEL) — Titan Protect Analysis

LYEL

Lyell Immunopharma Inc

Healthcare · ·

$11.97

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$296M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-15.12

Based on estimated future earnings — lower means cheaper

Rev Growth

-71.4%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-80.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$44.00

+268% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which i

https://www.lyell.com

Country: United States Employees: 161 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.186

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0408

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.595

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-50.9%

Historical annualised return based on price data

Max Drawdown

-85.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.06

Very low correlation to market moves

52W High

$45.00

73% below the year high

52W Low

$7.78

54% above the year low

Avg Volume

87,192

Average daily shares traded — higher means easier to buy and sell

Short Ratio

20.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-13.62

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

17.85

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-2,213,050.0%

Profit from core operations before interest and tax

Free Cash Flow

$-77,380,752

Negative — the business is spending more than it generates

Revenue (TTM)

$31,000

Total revenue over the last 12 months

Net Income

$-246,406,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$49.00

Target Median

$44.00

Target Low

$34.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go